140 related articles for article (PubMed ID: 30825015)
1. Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer.
Ozawa Y; Amano Y; Kanata K; Hasegwa H; Matsui T; Kakutani T; Koyauchi T; Tanahashi M; Niwa H; Yokomura K; Suda T
Med Oncol; 2019 Mar; 36(4):33. PubMed ID: 30825015
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.
Zhang F; Bai H; Gao R; Fei K; Duan J; Zhang Z; Wang J; Hu X
Cancer Immunol Immunother; 2020 Dec; 69(12):2599-2611. PubMed ID: 32591861
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Patil NS; Zou W; Mocci S; Sandler A; Ballinger M; Flynn S; Kowanetz M; Hegde PS
PLoS One; 2021; 16(2):e0246486. PubMed ID: 33534859
[TBL] [Abstract][Full Text] [Related]
4. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.
Inoue Y; Inui N; Karayama M; Asada K; Fujii M; Matsuura S; Uto T; Hashimoto D; Matsui T; Ikeda M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Suda T
Cancer Immunol Immunother; 2023 Aug; 72(8):2717-2728. PubMed ID: 37099186
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of some proinflammatory cytokines and biochemical parameters in pre and postmenopausal breast cancer women.
Mohammed Bakheet M; Mohssin Ali H; Jalil Talab T
Cytokine; 2024 Jul; 179():156632. PubMed ID: 38701734
[TBL] [Abstract][Full Text] [Related]
6. An On-Treatment Decreased Trend of Serum IL-6 and IL-8 as Predictive Markers Quickly Reflects Short-Term Efficacy of PD-1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer.
Liu J; Mao Y; Mao C; Wang D; Dong L; Zhu W
J Immunol Res; 2024; 2024():3604935. PubMed ID: 38774604
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer.
Ando K; Takahashi F; Kato M; Kaneko N; Doi T; Ohe Y; Koizumi F; Nishio K; Takahashi K
PLoS One; 2014; 9(7):e102436. PubMed ID: 25010770
[TBL] [Abstract][Full Text] [Related]
8. Can C-reactive protein be used as a surrogate marker of IL-6 in a broad array of clinical entities?
Ali SB; Cecchin A; Lucchesi C; Putty T; Edwards S; Petrou T; Coates P; Ferrante A; Pucar PA; King J; Banovic T
Biomark Med; 2023 Dec; 17(24):1001-1010. PubMed ID: 38235562
[No Abstract] [Full Text] [Related]
9. Plasma levels of 12 different cytokines correlate to PD-1 inhibitor combined chemotherapy responses in advanced non-small-cell lung cancer patient.
Peng Y; Qi Q; Zhu M; Zhang Y; Bao Y; Liu Y
Int Immunopharmacol; 2023 Nov; 124(Pt A):110888. PubMed ID: 37690239
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
[TBL] [Abstract][Full Text] [Related]
11. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Riedl JM; Barth DA; Brueckl WM; Zeitler G; Foris V; Mollnar S; Stotz M; Rossmann CH; Terbuch A; Balic M; Niedrist T; Bertsch T; Stoeger H; Pichler M; Olschewski H; Absenger G; Ficker JH; Gerger A; Posch F
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824580
[TBL] [Abstract][Full Text] [Related]
12. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC.
Keegan A; Ricciuti B; Garden P; Cohen L; Nishihara R; Adeni A; Paweletz C; Supplee J; Jänne PA; Severgnini M; Awad MM; Walt DR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020238
[TBL] [Abstract][Full Text] [Related]
13. Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors.
Chai R; Fan Y; Zhao J; He F; Li J; Han Y
Ann Transl Med; 2020 Sep; 8(17):1078. PubMed ID: 33145297
[TBL] [Abstract][Full Text] [Related]
14. Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors.
Kang DH; Park CK; Chung C; Oh IJ; Kim YC; Park D; Kim J; Kwon GC; Kwon I; Sun P; Shin EC; Lee JE
Immune Netw; 2020 Jun; 20(3):e27. PubMed ID: 32655975
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of soluble PD-1 and PD-L1 in lung cancer.
Abu Hejleh T; Furqan M; Ballas Z; Clamon G
Crit Rev Oncol Hematol; 2019 Nov; 143():148-152. PubMed ID: 31675543
[TBL] [Abstract][Full Text] [Related]
17. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors.
Iivanainen S; Ahvonen J; Knuuttila A; Tiainen S; Koivunen JP
ESMO Open; 2019; 4(4):e000531. PubMed ID: 31555483
[TBL] [Abstract][Full Text] [Related]
18. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
19. Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients.
Wang Y; Chen H; Zhang T; Yang X; Zhong J; Wang Y; Chi Y; Wu M; An T; Li J; Zhao X; Dong Z; Wang Z; Zhao J; Zhuo M; Huang J
Ann Transl Med; 2021 Jan; 9(1):33. PubMed ID: 33553326
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.
Schalper KA; Carleton M; Zhou M; Chen T; Feng Y; Huang SP; Walsh AM; Baxi V; Pandya D; Baradet T; Locke D; Wu Q; Reilly TP; Phillips P; Nagineni V; Gianino N; Gu J; Zhao H; Perez-Gracia JL; Sanmamed MF; Melero I
Nat Med; 2020 May; 26(5):688-692. PubMed ID: 32405062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
